Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
HER-2/neu expression used to prognosticate primary breast cancer
March 23rd, 2006
HER-2/neu expression could be used to predict sentinel lymph node (SLN) metastasis in primary breast cancer. According to a study from the United States, "Amplification of the protein product of the HER-2/neu oncogene in primary breast cancer specimens is associated with an adverse prognosis. We hypothesized that overexpression of HER-2/neu would predict metastases to the SLNs. A retrospective review of a prospective nonrandomized evaluation of 1055 clinically node-negative breast cancer patients undergoing 1063 SLN biopsies was performed." "HER-2/neu analysis was performed by immunohistochemistry and, in selected cases, by fluorescence in situ...
Source: Women's Health Weekly (2006-03-23)
|
